Christopher McNair
Overview
Explore the profile of Christopher McNair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlegel L, Brill-Edwards M, Wang Z, McNair C, Gargano S, Cottrill E
Head Neck
. 2025 Mar;
PMID: 40055996
Background: Data connecting PTEN mutations with thyroid cancer risk for indeterminate nodules remain limited due to the rare nature of these mutations. The aim of this study was to determine...
2.
Burus T, McAfee C, Hull P, Leader A, McNair C
J Natl Cancer Inst
. 2024 Sep;
117(2):335-337.
PMID: 39312690
The National Cancer Institute's (NCI) Cancer Center Support Grant mandates that NCI-designated cancer centers establish a Community Outreach and Engagement (COE) component to help direct efforts at reducing cancer burden...
3.
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, et al.
BMC Public Health
. 2024 Sep;
24(1):2533.
PMID: 39289635
Background: Black men consistently have higher rates of prostate cancer (PCA)- related mortality. Advances in PCA treatment, screening, and hereditary cancer assessment center around germline testing (GT). Of concern is...
4.
Burus T, Martinez J, DelNero P, Pepper S, Ratnayake I, Oh D, et al.
JCO Clin Cancer Inform
. 2024 Jul;
8:e2400099.
PMID: 39079076
No abstract available.
5.
Burus T, VanHelene A, Rooney M, Lang Kuhs K, Christian W, McNair C, et al.
JAMA Netw Open
. 2024 May;
7(5):e2410670.
PMID: 38758559
Importance: Proton beam therapy is an emerging radiotherapy treatment for patients with cancer that may produce similar outcomes as traditional photon-based therapy for many cancers while delivering lower amounts of...
6.
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300654.
PMID: 38547422
Clinical genomic testing of patient germline, tumor tissue, or plasma cell-free DNA can enable a personalized approach to cancer management and treatment. In prostate cancer (PCa), broad genotyping tests are...
7.
Gordon N, Gallagher P, Neupane N, Mandigo A, McCann J, Dylgjeri E, et al.
bioRxiv
. 2023 Mar;
PMID: 36993449
Results: Two distinct CRPC models were found to be sensitive to physiologically relevant doses of ascorbate. Moreover, additional studies indicate that ascorbate inhibits CRPC growth via multiple mechanisms including disruption...
8.
Urdang Z, Kargbo I, Noss E, McNair C, Jin H, Cottrill E, et al.
J Health Care Poor Underserved
. 2022 Dec;
33(4S):124-137.
PMID: 36533462
Despite increasingly stringent requirements from regulatory agencies, clinical trials often fail to recruit study populations representative of real-world demographics and disease prevalence and are often skewed away from racial/ethnic minorities....
9.
London J, Fazio-Eynullayeva E, Palchuk M, McNair C
JCO Clin Cancer Inform
. 2022 Mar;
6:e2100200.
PMID: 35258986
Purpose: This is an update to a previously published report characterizing the impact that efforts to control the COVID-19 pandemic have had on the normal course of cancer-related encounters. Methods:...
10.
Satyanarayana G, Enriquez K, Sun T, Klein E, Abidi M, Advani S, et al.
Open Forum Infect Dis
. 2022 Feb;
9(3):ofac037.
PMID: 35198648
Background: The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection. Methods:...